Testosterone phenylacetate

Testosterone phenylacetate (TPA; brand names Perandren, Androject) is an androgen and anabolic steroid and a testosterone ester.[1][2][3] Analogously to estradiol benzoate having been one of the first estrogen esters to be introduced, testosterone phenylacetate was one of the first testosterone esters to be introduced.[4] However, since its introduction, it has largely been replaced by other esters, such as testosterone propionate.[4]

Not to be confused with Testosterone propionate or Testosterone isobutyrate.
Testosterone phenylacetate
Clinical data
Trade namesPerandren, Androject
Other namesTPA
Routes of
administration		Intramuscular injection
Drug classAndrogen; Anabolic steroid; Androgen ester
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC27H34O3
Molar mass406.557 g·mol−1
3D model (JSmol)

Testosterone phenylacetate was a 50 mg/mL microcrystalline aqueous suspension under the brand name Perandren.[5][6][7][8][9] It was used at a dosage of 50 to 200 mg by intramuscular injection once every 2 to 5 weeks.[6][10] The medication was used to treat hypogonadism and eunuchoidism in males and for palliation of breast cancer in females.[8][9] It was developed by Ciba Pharmaceutical Company.[8] In 1955 it was claimed to have the longest duration of any clinically used androgen marketed up to that point.[11]

See also

References
  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–642. ISBN 978-1-4757-2085-3.
  2. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN 978-3-88763-075-1.
  3. I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. ISBN 978-94-011-4439-1.
  4. Walter Sneader (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 205–. ISBN 978-0-470-01552-0.
  5. Escamilla RF (February 1960). "Newer hormonal preparations". Calif Med. 92: 121–4. PMC 1578009. PMID 13849734.
  6. Milton John Chatton (1973). Current Diagnosis & Treatment. Lange Medical Publications. Testosterone Phenylacetate (Perandren Phenyl- acetate®): This microcrystalline aqueous suspension for intramuscular use has a prolonged action similar to Depo-Testosterone®. It is supplied as 10 ml vials of 50 mg/ml. The average dose is 50-200 mg every 3-5 weeks.
  7. Physicians Desk Reference to Pharmaceutical Specialties and Biologicals. Medical Economics. 1968. p. 624.
  8. Federal Register. Office of the Federal Register, National Archives and Records Service, General Services Administration. September 1977. pp. 52488–.
  9. John Christian Krantz; Charles Jelleff Carr; Domingo M. Aviado (1972). Krantz and Carr's Pharmacologic principles of medical practice: a textbook on pharmacology and therapeutics for students and practitioners of medicine, pharmacy, and dentistry. Williams & Wilkins. p. 670.
  10. Hans Lisser; Roberto F. Escamilla (1962). Atlas of Clinical Endocrinology. Mosby. Testosterone phenylacetate (Perandren phenylacetate)—Long-acting suspension of macrocrystals. Dose, 100 to 200 mg. intramuscularly every 2 to 4 weeks.
  11. Modern Drugs: The Journal of the Modern Drug Encyclopedia. Drug Publications. 1955.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.